Jean-Luc Lemercier
Corporate Vice President Edwards Lifesciences, EMEA, Canada, Latin America and JAPAC & Chair of the Cardiovascular Sector Group of MedTech Europe
Jean-Luc Lemercier has been corporate vice president, EMEA (Europe, Middle East and Africa), Canada and Latin America since July 2017. Prior to assuming his current role, Lemercier served as vice president of transcatheter heart valves EMEA since 2008. Under his leadership at Edwards, the company successfully launched the SAPIEN transcatheter heart valve technology and built its leadership position in Europe.
Before joining Edwards, Lemercier served various leadership roles with Johnson & Johnson Cordis from 1996-2008, including leader of the structural heart disease group in the United States; vice president of new business development in Europe and vice president of the Cordis cardiology division in Belgium; and general manager of Cordis France. Lemercier has more than 30 years of medical device experience, beginning with Baxter in France, and held several sales and marketing management positions within Baxter Europe and the United States.
Lemercier holds a degree as a doctor in pharmacy from the Claude Bernard Lyon 1 University in Lyon, France.
He also serves as Chair of the Cardiovascular Sector Group of MedTech Europe.
6 blogs from the author
Posted on 29.09.2023
Time To Act To Change The Beat: Tackling Cardiovascular disease has never been more urgent
On this World Heart Day, it is crucial to stand together in our call to achieve better cardiovascular health for all. As chair of the MedTech Europe Cardiovascular Sector Group, I feel the need to underline once again the urgency of addressing this issue. Cardiovascular disease (CVD) is more than a health concern; it’s an […]
Posted on 27.09.2021
New EU Alliance will put cardiovascular health in the spotlight
Despite significant advances in recent decades to improve cardiovascular care and reduce mortality, the burden of cardiovascular disease (CVD) remains greater than any other disease. A concerted effort is needed to ensure the voices of stakeholders are heard by policymakers and that cardiovascular health is prioritised accordingly. That is why we have come together just […]
Posted on 27.05.2021
The need for an EU Action Plan for better cardiovascular health
Did you know that every day, some 5,000 people die from cardiovascular diseases (CVDs), amounting to 1.8 million deaths every year? This, unfortunately, makes cardiovascular disease – including heart failure, stroke-related atrial fibrillation, heart valve disease and coronary heart disease – the number one killer in Europe. The COVID-19 pandemic has radically changed the way we […]
Posted on 29.09.2020
Your heart has never been more important
The unprecedented COVID-19 has fundamentally shifted society’s and government’s attention and prioritisation of healthcare. Never has health topped our agenda as much as today – as an individual trying to stay healthy, as healthcare professional and facility trying to deliver a high quality of care, as industry trying to deliver the best innovations to improve […]
Posted on 17.12.2019
The 3 ways in which the EU can improve peoples’ heart health
Even in 2019, cardiovascular diseases (CVD) remain the number 1 killer globally, accounting for almost 2 million deaths in the EU alone every year. These diseases are linked to huge inequalities, with more cardiovascular-related deaths in women than men, and more CVD-related deaths in middle-income than high-income countries, as a recent study from the European […]
Posted on 01.02.2019
Putting Health and Innovation at the heart of a European Social Contract
Given that the number of Europeans aged over 65 will double in the next 50 years, and the number of over 80 year olds will almost triple, it follows that keeping this age group in good health is a particular priority. However, European healthcare systems are at a tipping point, driven by the increasing burden […]
Medtech Views
Curated by
